세계의 염증성 장질환(IBD) 치료제 시장

Global Inflammatory Bowel Disease (IBD) Therapeutics Market to Reach US$32.8 Billion by 2030

The global market for Inflammatory Bowel Disease (IBD) Therapeutics estimated at US$23.2 Billion in the year 2023, is expected to reach US$32.8 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2023-2030. TNF inhibitors, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$14.0 Billion by the end of the analysis period. Growth in the Anti-integrin segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.1 Billion While China is Forecast to Grow at 8.2% CAGR

The Inflammatory Bowel Disease (IBD) Therapeutics market in the U.S. is estimated at US$6.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$7.6 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 4.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Inflammatory Bowel Disease (IBD) Therapeutics - Key Trends and Drivers

Inflammatory Bowel Disease (IBD) therapeutics encompasses a range of treatments designed to manage and alleviate the symptoms of chronic inflammatory conditions of the gastrointestinal tract, primarily Crohn's disease and ulcerative colitis. These conditions cause severe inflammation, leading to symptoms such as abdominal pain, diarrhea, rectal bleeding, and weight loss. The primary goal of IBD therapeutics is to induce and maintain remission, reduce inflammation, and improve patients' quality of life. Treatment options include aminosalicylates, corticosteroids, immunomodulators, biologics, and, more recently, small molecule drugs. Biologics, which target specific components of the immune system, have revolutionized IBD treatment, providing relief for patients who do not respond to traditional therapies. However, the complexity of IBD, with its varying presentations and patient responses, necessitates a personalized approach to treatment.

Technological advancements and ongoing research are significantly impacting the IBD therapeutics landscape. The development of novel biologic therapies and biosimilars has expanded the range of treatment options available to patients. These therapies, including TNF inhibitors, integrin inhibitors, and interleukin inhibitors, offer targeted mechanisms of action that help control inflammation more effectively and with fewer side effects than conventional treatments. Additionally, advancements in precision medicine and pharmacogenomics are enabling more personalized treatment strategies, optimizing therapeutic outcomes based on individual patient profiles. Non-invasive diagnostic tools, such as advanced imaging techniques and biomarkers, are improving the ability to monitor disease activity and treatment response, allowing for more timely and accurate adjustments to therapeutic regimens. Furthermore, digital health technologies, including mobile health apps and telemedicine, are enhancing patient management and adherence to treatment plans by facilitating better communication between patients and healthcare providers.

The growth in the IBD therapeutics market is driven by several factors, including the increasing prevalence of IBD, technological innovations, and greater awareness and diagnosis of the condition. The rising incidence of IBD globally, particularly in developed regions, is significantly expanding the patient population in need of effective treatments. Technological advancements in biologic therapies and the development of biosimilars are reducing treatment costs and making advanced therapies more accessible. The integration of precision medicine into IBD treatment protocols is leading to more effective and personalized therapeutic approaches, improving patient outcomes and satisfaction. Additionally, the adoption of digital health technologies is facilitating better disease management and patient engagement, driving adherence to treatment plans. Regulatory support for novel therapies and expedited approval processes for new drugs are also contributing to market growth. Moreover, ongoing clinical trials and research into the pathophysiology of IBD are paving the way for the development of next-generation therapeutics, promising even more effective and targeted treatment options in the future. These combined factors underscore the dynamic and rapidly evolving nature of the IBD therapeutics market.

Select Competitors (Total 69 Featured) -

• 4SC AG
• Abbott Nutrition
• AbbVie, Inc.
• Ablynx NV
• Active Biotech AB
• Alfasigma S.p.A.
• Allergan PLC
• Allergan PLC
• Amgen, Inc.
• Astellas Pharma, Inc.
• AstraZeneca PLC
• Athersys, Inc.
• Atlantic Healthcare plc
• Avaxia Biologics, Inc.
• Biosafe Systems, LLC
• Boehringer Ingelheim GmbH
• Cadila Healthcare Ltd.
• Celgene Corporation
• Celltrion, Inc.
• Cipla Ltd.
• Coherus Biosciences, Inc.
• Cosmo Pharmaceuticals NV
• Dr. Falk Pharma GmbH
• EA Pharma Co., Ltd.
• Eddingpharm
• EPIRUS Biopharmaceuticals, Inc.
• F. Hoffmann-La Roche AG
• F. Hoffmann-La Roche AG
• Galapagos NV
• Giaconda Ltd.
• Google LLC
• Immunic, Inc.
• InDex Pharmaceuticals Holding AB
• Infinity Pharmaceuticals, Inc.
• Ionis Pharmaceuticals, Inc.
• Janssen Biotech, Inc.
• Johnson & Johnson
• Kissei Pharmaceutical Co., Ltd.
• LG Sciences
• Lupin Ltd.
• Mochida Pharmaceutical Co., Ltd.
• Mylan Pharmaceutical Pvt. Ltd.
• Neovacs SA
• Nogra Pharma Limited
• NovaMedica LLC
• Novartis International AG
• Osiris Therapeutics, Inc.
• Otsuka Pharmaceutical Co., Ltd.
• PAR Pharmaceutical Companies, Inc.
• PendoPharm, Inc.
• Perrigo Company PLC
• Pfenex, Inc.
• Pfizer, Inc.
• Pharmascience Inc.
• Pluristem Therapeutics, Inc.
• Qu Biologics Inc.
• Quest Diagnostics, Inc.
• RedHill Biopharma Ltd.
• Reliance Life Sciences
• Salix Pharmaceuticals, Inc.
• Sandoz International GmbH
• Sanofi
• Sequella, Inc.
• Soligenix, Inc.
• Takeda Pharmaceutical Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• Toray Industries, Inc.
• Torrent Pharmaceuticals Ltd.
• UCB SA
• Zeria Pharmaceutical Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Inflammatory Bowel Disease (IBD) Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of IBD Throws the Spotlight on Growing Therapeutic Needs
  • Technological Innovations in Biologic Therapies Propel Growth in IBD Treatment Options
  • Increasing Adoption of Biosimilars Expands Addressable Market Opportunity
  • Advancements in Precision Medicine Strengthen Business Case for Personalized IBD Therapies
  • Integration of Digital Health Technologies Drives Adoption of Remote Patient Management Solutions
  • Enhanced Non-Invasive Diagnostic Tools Generates Demand for Advanced Monitoring Techniques
  • Growing Awareness and Early Diagnosis of IBD Improves Patient Outcomes
  • Ongoing Clinical Trials and Research into Pathophysiology to Shape Future Therapeutics
  • Patient Demand for Minimally Invasive Treatments Drives Adoption of New Drug Delivery Methods
  • Increasing Investment in Healthcare Infrastructure Expands Addressable Market Opportunity
  • Shift towards Personalized Medicine Generates Demand for Tailored IBD Therapeutic Approaches
  • Rising Incidence of IBD in Developed Regions Strengthens Business Case for Market Expansion
  • Development of Next-Generation Therapeutics Create New Market Opportunities
  • Economic and Social Impact of IBD Propels Demand for Effective Long-Term Treatments
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Inflammatory Bowel Disease (IBD) Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for TNF inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for TNF inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for TNF inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Anti-integrin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Anti-integrin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Anti-integrin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Aminosalicylates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Aminosalicylates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Aminosalicylates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for IL inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for IL inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for IL inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for JAK inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for JAK inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for JAK inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Crohn's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Crohn's Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: World 16-Year Perspective for Crohn's Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Ulcerative Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Ulcerative Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: World 16-Year Perspective for Ulcerative Colitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: World 16-Year Perspective for Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: World 16-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: World 16-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: World 16-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 47: USA Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: USA 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: USA 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: USA 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: USA 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: Canada 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: Canada 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: Canada 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: Canada 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• JAPAN
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Japan 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Japan 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: Japan 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: Japan 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• CHINA
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 83: China Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: China 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: China 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 89: China Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: China 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 92: China Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: China 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• EUROPE
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Europe 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Europe 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Europe 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Europe 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: Europe 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• FRANCE
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 110: France Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: France 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 113: France Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: France 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 116: France Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: France 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 119: France Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 121: France 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• GERMANY
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 124: Germany 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 127: Germany 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 130: Germany 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 133: Germany 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 136: Italy 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 139: Italy 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 142: Italy 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 145: Italy 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 146: UK Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 148: UK 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 149: UK Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 151: UK 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 152: UK Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 154: UK 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 155: UK Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 157: UK 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 160: Spain 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 163: Spain 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 166: Spain 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 169: Spain 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 172: Russia 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 175: Russia 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 178: Russia 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 181: Russia 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 184: Rest of Europe 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 187: Rest of Europe 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 190: Rest of Europe 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 193: Rest of Europe 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 196: Asia-Pacific 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 199: Asia-Pacific 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 202: Asia-Pacific 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 205: Asia-Pacific 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 208: Asia-Pacific 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 211: Australia 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 214: Australia 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 217: Australia 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 220: Australia 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• INDIA
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 221: India Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 223: India 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 224: India Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 226: India 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 227: India Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 229: India 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 230: India Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 232: India 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 235: South Korea 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 238: South Korea 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 241: South Korea 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 244: South Korea 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 259: Latin America 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 262: Latin America 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 265: Latin America 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 268: Latin America 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 271: Latin America 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 274: Argentina 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 277: Argentina 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 280: Argentina 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 283: Argentina 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 286: Brazil 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 289: Brazil 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 292: Brazil 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 295: Brazil 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 298: Mexico 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 301: Mexico 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 304: Mexico 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 307: Mexico 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 310: Rest of Latin America 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 313: Rest of Latin America 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 316: Rest of Latin America 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 319: Rest of Latin America 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 322: Middle East 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 325: Middle East 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 328: Middle East 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 331: Middle East 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 334: Middle East 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 337: Iran 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 340: Iran 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 343: Iran 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 346: Iran 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 349: Israel 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 352: Israel 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 355: Israel 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 358: Israel 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 361: Saudi Arabia 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 364: Saudi Arabia 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 367: Saudi Arabia 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 370: Saudi Arabia 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 373: UAE 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 376: UAE 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 379: UAE 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 382: UAE 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 385: Rest of Middle East 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 388: Rest of Middle East 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 391: Rest of Middle East 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 394: Rest of Middle East 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030
• AFRICA
  • Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 397: Africa 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2014, 2024 & 2030
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn's Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 400: Africa 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn's Disease and Ulcerative Colitis for the Years 2014, 2024 & 2030
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 403: Africa 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2014, 2024 & 2030
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 406: Africa 16-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2024 & 2030

IV. COMPETITION